Clinical Trials

The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is more effective than Cyclosporine in inducing long term remission of proteinuria.

This is an open-label, multicentre study to characterize the safety and effectiveness of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory).

The study is being done to look for markers in the blood and/or stored kidney biopsy tissue, in patients with a history of childhood onset Membranous Nephropathy. By collecting health information and laboratory samples, our goal is to learn more about membranous nephropathy.

Due to discovery of additional antibodies and antigens (Thrombospondin Type-1 Domain 7A, Semaphorin 3B, Exotosin-1 & 2, Neural epidermal growth factor-like type 1, Protocadherin 7 PCDH7, Protocadherin FAT1, and serine protease HTRA1) in children with MN over the last decade, we would like to expand serological and hisotological testing of these antibodies and antigens in the existing and archived ...

The purpose of this study is to assess the effect of aliskiren to keep protein from spilling into the urine in patients who have idiopathic membranous nephropathy.

The purpose of this study is to evaluate the effectivess and safety of Obinutuzumab as compared to Tacrolimus in patients with Primary Membranous Nephropath (pMN).

The purpose of this study is to assess the safety and tolerability of MOR202 treatment in subjects with Antibody Positive Membranous Nephropathy (aMN).

Membranous glomerulopathy (MN) is still the most common glomerular disease associated with nephrotic proteinuria (NS). Up to 40% of patients reach end stage renal failure (ESRD), making MN the 2nd or 3rd most common cause of ESRD caused by a primary glomerulopathy. Current treatment options include corticosteroids, alkylating agents, and cyclosporin, but their use is controversial and the associated adverse effects and high cost temper their usage. Experimental data in MN suggests that B cell activation results in immunoglobulin deposition along the glomerular basement membrane causing injury to the membrane and subsequent proteinuria. Drugs that non-selectively inhibit B cells and, ...

The primary objective of this study is to determine the effectiveness of belimumab with rituximab at inducing a complete or partial remission (CR or PR) compared to rituximab alone in patients with Primary Membranous Nephropathy (PM).

The purpose of this study is to provide nephrologists with additional clinical evidence regarding the efficacy and safety of Acthar in subjects with treatment-resistant idiopathic membranous nephropathy. Approximately sixty (60) subjects will be randomized in this double-blind, parallel-group, placebo-controlled, multicenter study comparing Acthar and Placebo administered 2 times per week for a 24-week treatment period followed by a 24-week observation period. The primary objective of this study is to assess the proportion of treatment-resistant subjects (defined as subjects who either have had no response or have suffered a relapse after achieving a partial response to their most recent standard treatment ...

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and ...

The purpose of this registry is to establish a database of patients diagnosed with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or immunoglobulin A nephropathy (IgAN), to advance the diagnosis and care of patients with glomerular diseases.

The purpose of this study is to develop urine tests that will measure biological markers and use them to track the status of kidney disease. This test may help doctors to better care for patients with kidney disease.

This study is being done to create a "resource" of samples that can be used to improve our ability to diagnose and treat MN, IgAN, MPGN, FSGS/MCD, Lupus Nephritis, AAV, other glomerular tubulo-interstitial disease.